Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
BURLINGAME, Calif., Aug. 11, 2017 -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the 2017 Wedbush PacGrow Healthcare Conference in New York City, New York. The presentation is scheduled for Wednesday, August 16, at 1:20pm Eastern Time.
A webcast of the presentation will be available live and for 30 days following the event. The webcast may be accessed via http://wsw.com/webcast/wedbush33/crvs and from the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit: www.corvuspharma.com.
Tecentriq® (atezolizumab) is a registered trademark of Genentech.
Corvus Contact: Guillermo Elias, PhD Director, Business Development Corvus Pharmaceuticals, Inc. +1-650-889-4377 [email protected] Media Contact: Julie Normart Pure Communications +1-415-946-1087 [email protected]
